In the first half of 2021, Datwyler’s revenue from continuing operations grew dynamically by 20.8% to CHF 590.0 million. Thanks to the good utilisation of capacity and strict cost management, the operating result (EBIT) rose disproportionately by 53.3% to CHF 98.9 million. The EBIT margin improved by more than three percentage points to 16.8%. These figures are already above pre-pandemic levels of 2019. Despite the ongoing uncertainty caused by the pandemic, Datwyler has increased its forecasts for the year as a whole for revenue and EBIT margin to over CHF 1’150 million and above 16%, respectively, due to the progress made in the global vaccination campaigns and the strength of the economy.

Visit of the European FirstLine® plant on Investor Day Several structural trends are sustaining growth in the global health care market. Depending on the subsegment and world region, annual growth for components for injectable drugs is over 10%. With its leading first line manufacturing standard and global presence, Datwyler is best positioned to capitalize on these growth opportunities. On the Investors' Day, investors, analysts and journalists will be given an insight into the FirstLine® plant in Belgium. The previous annual targets for sales and EBIT margin are confirmed.

The Datwyler Group is holding an Investors' Day on 15 November. The aim is to give investors, analysts and the media a deeper insight into the activities for the health care market. As communicated, Datwyler's Sealing Solutions division is opening a new plant with FirstLine production standards in the USA this autumn. For this reason, the Group would like to present this industry-leading FirstLine standard with a tour on the Investors' Day. The event will therefore take place at the site of the European Datwyler FirstLine plant in Alken, Belgium.